Statistics

Total Visits

Views
A Phase IIb Dose-Ranging Study of the Oral JAK Inhibitor Tofacitinib (CP-690,550) Versus Placebo in Combination With Background Methotrexate in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate Alone355

Select a period of time:

Number of views in the range

Views
A Phase IIb Dose-Ranging Study of the Oral JAK Inhibitor Tofacitinib (CP-690,550) Versus Placebo in Combination With Background Methotrexate in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate Alone252

Views

Views
November 20255
December 202524
January 202650
February 20263
March 202613
April 20262
May 2026155
Download CSV file
 untranslated
 untranslated

Top country views

Views
Ireland140
Finland61
United States32
United Kingdom5
France3
Brazil3
Singapore2
Kenya2
Canada1
Guatemala1
 

Top cities views

Views
Dublin140
Helsinki61
San Jose12
Palo Alto7
Phoenix3
São Paulo2
Waltham Forest2
Santa Clara2
Appleton1
Atlanta1